- Your selection
- Clear all
- Pharmaceuticals x
- English x
- Europe x
19 case(s) found.
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
Reference 6031
Published 27 Jan 2014
Length 11 page(s)
Region Europe
Industry Pharmaceuticals
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
Reference 6031
Published 27 Jan 2014
Length 6 page(s)
Region Europe
Industry Pharmaceuticals
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
This case describes the successful implementation of sustainable operations at Pfizer's Freiburg production facility in Germany. It charts the planning and execution of an ambitious portfolio of projects directed toward energy efficiency, with significant financial, social and environmental impacts.
Reference 5680
Published 25 Mar 2010
Length 17 page(s)
Topic Operations
Region Europe
Industry Pharmaceuticals
This case describes the successful implementation of sustainable operations at Pfizer's Freiburg production facility in Germany. It charts the planning and execution of an ambitious portfolio of projects directed toward energy efficiency, with significant financial, social and environmental impacts.
Faced with increasing parallel imports, Pfizer in Europe decides to change its drug distribution strategy. It introduces a 'Direct to Pharmacy' scheme whereby distributors become mere logistics companies. Pfizer also introduces 'dual pricing' to force wholesalers to sell the drugs in the targeted country.
Reference 5679
Published 23 Feb 2011
Length 31 page(s)
Topic Strategy
Region Europe
Industry Pharmaceuticals
Faced with increasing parallel imports, Pfizer in Europe decides to change its drug distribution strategy. It introduces a 'Direct to Pharmacy' scheme whereby distributors become mere logistics companies. Pfizer also introduces 'dual pricing' to force wholesalers to sell the drugs in the targeted country.
Amgen Europe has launched Aranesp, a second-generation EPO product in a market dominated by Johnson & Johnson's pioneering Eprex (US name Procrit), followed by NeoRecormon from Roche. One year after the launch, the sales and market share of Aranesp are below target.
Reference 5410
Published 04 Jan 2007
Length 19 page(s)
Topic Marketing
Region Europe
Industry Pharmaceuticals
Amgen Europe has launched Aranesp, a second-generation EPO product in a market dominated by Johnson & Johnson's pioneering Eprex (US name Procrit), followed by NeoRecormon from Roche. One year after the launch, the sales and market share of Aranesp are below target.
NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.
Reference 5381
Published 07 Jan 2006
Length 31 page(s)
Topic Marketing
Region Europe
Industry Pharmaceuticals
NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.
Organon France is the first company to implement a physician-focused customer relationship management (CRM) system. The case describes the different channels through which Organon communicates with physicians, the rationale and metrics for the CRM system, the main steps in CRM implementation, and the issues arising during the actual utilization of the system by the sales force and marketing.
Reference 5269
Published 31 May 2005
Length 22 page(s)
Topic Marketing
Region Europe
Industry Pharmaceuticals
Organon France is the first company to implement a physician-focused customer relationship management (CRM) system. The case describes the different channels through which Organon communicates with physicians, the rationale and metrics for the CRM system, the main steps in CRM implementation, and the issues arising during the actual utilization of the system by the sales force and marketing.
In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beechams (SB) blockbuster antibiotic.
Reference 5057
Published 01 Jun 2003
Length 25 page(s)
Topic Marketing
Region Europe
Industry Pharmaceuticals
In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beechams (SB) blockbuster antibiotic.
The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?
Reference 5057
Published 06 Jan 2003
Length 1 page(s)
Topic Marketing
Region Europe
Industry Pharmaceuticals
The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?
The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
Reference 4927
Published 01 Dec 2000
Length 11 page(s)
Topic Economics & Finance
Region Europe
Industry Pharmaceuticals
The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
Abstract: See Advanced Drug Delivery Systems: ALZA and Ciba-Geigy (A) - (F).
Reference 4242
Published 01 Jan 1988
Length 8 page(s)
Topic Strategy
Region Europe
Industry Pharmaceuticals
Abstract: See Advanced Drug Delivery Systems: ALZA and Ciba-Geigy (A) - (F).
Reference 4242
Published 31 Dec 1999
Length 14 page(s)
Topic Strategy
Region Europe
Industry Pharmaceuticals
